AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Short-term intravenous proton pump inhibitors and histamine H2 antagonists do not negatively affect sustained virologic response in hepatitis C cirrhotic patients treated with ledipasvir or velpatasvir containing antiviral regimens: a case seriesView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019High incidence of drug-drug interactions with hepatitis C direct-acting antivirals in patients hospitalized during their treatmentView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Effect of tenofovir and bacavir on dolutegravir transport in vitro and in vivoView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Comparison of relative bioavailability of pediatric triumeq and pediatric dolutegravir/lamivudine dispersible tablets to conventional film coated tablets in healthy adultsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Influence of SLCO1B1 polymorphisms on lopinavir plasma concentration in Serbian HIV/AIDS patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Sofosbuvir and 007 pharmacokinetics among persons with HCV and active drug useView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Tenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patientsView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019HBV infections among HIV-infected mothers on ART and their exposed infants in a tertiary hospital, Nairobi KenyaView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Model-based simulted 3TC exposure in HIV population by varying renal functionView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019PBPK modelling and simulation of ritonavir-boosted atazanavir (ATV/r) dosing when co-administered with rifampicin (RIF)View Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Alteration of hepatic OATP activity does not alter the pharmacodynamic effect of GS-0976, a liver targeted ACC inhibitor, on de novo lipogenesisView Abstract
AbstractHIVViral Hepatitis and Liver DiseaseInternational Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019Pharmacokinetic (PK) and pharmacocokinetic/pharmacodynamic characterization of the two-drug anti-retroviral regimen (2DR) dolutegravir/rilpivirine following switch from current anti-retroviral therapy in the SWORD-1 and SWORD-2 Phase 3 studiesView Abstract
